These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35910024)

  • 1. Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
    Yi Q; Peng J; Xu Z; Liang Q; Cai Y; Peng B; He Q; Yan Y
    Front Bioeng Biotechnol; 2022; 10():806851. PubMed ID: 35910024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.
    Wang Y; Zhao Y; Zhang G; Lin Y; Fan C; Wei H; Chen S; Guan L; Liu K; Yu S; Fu L; Zhang J; Yuan Y; He J; Cai H
    Sci Rep; 2024 Oct; 14(1):24203. PubMed ID: 39406840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of zinc and ring finger 3 in prognostic value and pan-cancer immunity.
    Liu M; Zhao H; Peng S; Wu Y; Liu Y; Sun W; Zen K; Sun X
    FASEB J; 2024 Mar; 38(5):e23523. PubMed ID: 38457275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pan-cancer analysis of the role of
    Ding G; Ma T; Zhang K; Chen G; Shen J; Zhang S; Li K; Zhao C; Wang F; Sun J; Wang J
    Biotechnol Genet Eng Rev; 2024 Nov; 40(3):1456-1471. PubMed ID: 36971139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
    Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
    Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCND1 as a Prognostic and Diagnostic Biomarker and the Impact of Its Epigenetic Alterations on Cancer Survival.
    Taha MY; Mohamed NO; Alhaj LG; Altayeb I; Basheer A; Idrees S; Said AM; Alfaki M
    Cureus; 2024 Jul; 16(7):e65504. PubMed ID: 39188436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
    Liu H; Zhang B; Sun Z
    Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
    Fei L; Lu Z; Xu Y; Hou G
    Front Genet; 2022; 13():920897. PubMed ID: 36035140
    [No Abstract]   [Full Text] [Related]  

  • 13. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
    Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
    Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
    Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
    Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
    Li L; Feng Q; Wang X
    Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
    Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
    Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
    Li J; Hu K; Zhou L; Huang J; Zeng S; Xu Z; Yan Y
    Front Oncol; 2020; 10():560615. PubMed ID: 33178590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of
    Zhang Y; Wu D; Yu T; Liu Y; Zhao C; Xue R
    Heliyon; 2024 Oct; 10(19):e38308. PubMed ID: 39397950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.
    Zhou Z; Peng B; Li J; Gao K; Cai Y; Xu Z; Yan Y
    Sci Rep; 2021 Sep; 11(1):18366. PubMed ID: 34526571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.